LLY - Rising Trend Channel [Mid Term]- LLY is in a rising trend channel in the medium long term.
- LLY has also received a positive signal from the moving average indicator, thus signaling a continued rise.
- LLY has broken up through resistance at 375.
- The short term momentum of the stock is strongly positive, with RSI above 70.
- Overall assessed as technically positive for the medium long term.
*EP: Enter Price, SL: Support, TP: Take Profit, CL: Cut Loss, TF: Time Frame, RST: Resistance, RTS: Resistance to be Support LT TP: Long Term Target Price
*Chart Pattern:
DT - Double Top | BEARISH | RED
DB - Double Bottom | BULLISH | GREEN
HNS - Head & Shoulder | BEARISH | RED
REC - Rectangle | BLUE
iHNS - inverse head & Shoulder | BULLISH | GREEN
Verify it first and believe later.
WavePoint ❤️
LLY
ELI LILLY on the best buy opportunity of the year!Eli Lilly and Company (LLY) has been trading within a Channel Up pattern since the October 30 2020 low exactly on the 1W MA100 (red trend-line). As the 1D RSI turned oversold below the 30.00 barrier, while the price touched the bottom (Higher Lows trend-line) of the Channel Up, it has filled all conditions for the most optimal buy level of the year. There have been another three similar oversold events, each on one year since 2020.
Once the price breaks above the 1D MA200 (orange trend-line) again, which you can use as confirmation and take the buy after it, we'll set a target at $390.00 on a 4 month horizon.
-------------------------------------------------------------------------------
** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! **
-------------------------------------------------------------------------------
💸💸💸💸💸💸
👇 👇 👇 👇 👇 👇
LLY | LongThis week a Twitter user bought a blue tick by spending $8 to post a fake tweet "insulin will be free now". Major Insulin producer LLY erased $30 billion in market cap. in a single day. Fundamentally this stock has a huge P/E ratio, in spide, there still has growth potential for that underlying. IMO LLY will retest new highs.
LLYthe health services and health technology sectors were the first to receive investment and bullish speculative pressures as the dollar fell
that is, drugs and vaccines never go into crisis .. even LLY has never even dropped below the 200 daily moving average this year, like very few stocks
and has now confirmed a bullish symmetrical triangle, I buy now and on GAP 343 retracement
MSFT SHORT
study(title="BestIntradayTips", shorttitle="BIT", precision=0, overlay=true, scale=scale.left)
trendDetectionLength=input(2)
showDistributionBelowZero=input(false, type=bool)
mov = close>close ? 1 : close= dif
wave=(trend != nz(wave )) and isTrending ? trend : nz(wave )
vol=wave==wave ? (nz(vol )+volume) : volume
up=wave == 1 ? vol : 0
dn=showDistributionBelowZero ? (wave == 1 ? 0 : wave == -1 ? -vol : vol) : (wave == 1 ? 0 : vol)
input_src = wave == 1 ? vol : 0
input_ma_period = input(50, title="Moving average")
input_max_height = input(1000, title="Maximum value on left bar")
ma = sma(input_src, input_ma_period)
normalized_volume = min(input_src / ma * 100, input_max_height * 1)
plot(input_max_height, transp=100, title="")
//
input_src1 = showDistributionBelowZero ? (wave == 1 ? 0 : wave == -1 ? -vol : vol) : (wave == 1 ? 0 : vol)
input_ma_period1 = input(50, title="Moving average")
input_max_height1 = input(1000, title="Maximum value on left bar")
hline(0)
hline(250)
hline(500)
hline(750)
ma1 = sma(input_src1, input_ma_period1)
normalized_volume1 = min(input_src1 / ma1 * 100, input_max_height1 * 1)
resCustom = input(title="Timeframe", type=resolution, defval="1440" )
v=security(tickerid, resCustom,normalized_volume)
resCustom1 = input(title="Timeframe", type=resolution, defval="1440" )
v1=security(tickerid, resCustom,normalized_volume1)
a=v>0 and v1<50
b=v1>0 and v<50
bgcolor(a > 0 ? blue : na, transp=80)
bgcolor(b > 0 ? red : na, transp=80)
$LLY looks ready to breakout$LLY daily chart. IT closed nicely on Friday even though most of the stocks were down a lot. After an up move, it is now moving sideways inside this rectangular range. Looks ready for next upmove once we break this range on the upside. Once we break above 335, looking for a 8% up move in this one.
7/17/22 LLYEli Lilly and Company ( NYSE:LLY )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $315.073B
Current Price: $331.60
Breakout price: $334.70
Buy Zone (Top/Bottom Range): $314.00-$292.90
Price Target: $364.20-$367.50 (2nd)
Estimated Duration to Target: 112-120d (2nd)
Contract of Interest: $LLY 10/21/22 350c
Trade price as of publish date: $13.50/contract
3/13/22 LLYEli Lilly and Company ( NYSE:LLY )
Sector: Health Technology (Pharmaceuticals: Major)
Market Capitalization: $253.61B
Current Price: $266.30
Breakout price: $270.95 (hold above)
Buy Zone (Top/Bottom Range): $262.45-$247.10
Price Target: $308.00-$310.40
Estimated Duration to Target: 84-90d
Contract of Interest: $LLY 6/17/22 300c
Trade price as of publish date: $5.90/contract
Eli Lilly up and up. LLYShort term and temporarily.
Immediate targets 257, 263, 272. Invalidation 232.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in green with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
$BIIB: Update, get long!I think it warrants making a new publication here, $BIIB has flashed a buy signal with tremendously good reward to risk, as it can resume the long term trend that can take it over $1600-2600 over time. Phase 3 clinical trials have gone really well for their Alzheimer's treatment 'Aduhelm', putting it in line with results obtained by $LLY's drug 'Donanemab'. I was long $LLY and have been trading in and out of $BIIB trying to time the end of the long slide since the FDA approval news came out. I think the time is now, to get in and sit tight. I've banked my $LLY exposure, but both companies will likely do well with their Alzheimer's treatments going forward and have solid trends, but the reward to risk favors $BIIB, so I'm only long Biogen currently.
Best of luck!
Cheers,
Ivan.
Flat on Eli Lilly. LLYWe are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe!
LLY Long Opportunity LLY has provided a nice long opportunity with the recent break above the major trendline
This breakout is comparable to a previous point, which led to a large megaphone price structure
Price will likely stay above the trendline and climb within the megaphone (attempted to roughly sketch what it would look like)
LLY - STOCKS - 21. OCT. 2021Welcome to our Weekly V2-Trade Setup ( LLY ) !
-
4 HOUR
Small pullback towards previous sr level.
DAILY
Expecting more bullish pa!
WEEKLY
Overall great market structure.
-
STOCK SETUP
BUY LLY
ENTRY LEVEL @ 241.21
SL @ 231.90
TP @ Open
Max Risk: 0.5% - 1%!
(Remember to add a few pips to all levels - different Brokers!)
Leave us a comment or like to keep our content for free and alive.
Have a great week everyone!
ALAN